Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BRS051
MIFTS: 58

Breast Disease

Categories: Reproductive diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Breast Disease

About this section

MalaCards integrated aliases for Breast Disease:

Name: Breast Disease 12 15 17
Breast Diseases 54 42 43 71

Classifications:

MalaCards categories:
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:3463
MeSH 43 D001941
NCIt 49 C26709
SNOMED-CT 67 79604008
UMLS 71 C0006145
Sources

Summaries for Breast Disease

About this section
MedlinePlus : 42 Most women experience breast changes at some time. Your age, hormone levels, and medicines you take may cause lumps, bumps, and discharges (fluids that are not breast milk). If you have a breast lump, pain, discharge or skin irritation, see your health care provider. Minor and serious breast problems have similar symptoms. Although many women fear cancer, most breast problems are not cancer. Some common breast changes are Fibrocystic breast changes - lumpiness, thickening and swelling, often just before a woman's period Cysts - fluid-filled lumps Fibroadenomas - solid, round, rubbery lumps that move easily when pushed, occurring most in younger women Intraductal papillomas - growths similar to warts near the nipple Blocked milk ducts Milk production when a woman is not breastfeeding NIH: National Cancer Institute

MalaCards based summary : Breast Disease, also known as breast diseases, is related to microglandular adenosis and hypertrophy of breast, and has symptoms including pruritus, exanthema and pelvic pain. An important gene associated with Breast Disease is PRLR (Prolactin Receptor), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Hydrocortisone acetate and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include breast, thyroid and lymph node, and related phenotypes are Decreased viability with paclitaxel and Decreased viability with paclitaxel

Disease Ontology : 12 A thoracic disease that is located in the breast.

Wikipedia : 74 Breast diseases make up a number of conditions. The most common symptoms are a breast mass, breast pain,... more...

Sources

Related Diseases for Breast Disease

About this section

Diseases related to Breast Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 408)
# Related Disease Score Top Affiliating Genes
1 microglandular adenosis 34.0 TP53 PGR ESR1 ERBB2
2 hypertrophy of breast 33.1 TP53 PGR ESR1 ERBB2 BRCA1
3 breast fibroadenoma 32.1 TP53 TFF1 PGR ESR1 ERBB2 CTSD
4 breast cancer 32.0 VEGFA TP53 TFF1 RHOC PRLR PGR
5 in situ carcinoma 31.9 TP53 PGR KRT5 ESR1 ERBB2 EGF
6 papilloma 31.8 VEGFA TP53 KRT5 ESR1 CASP3
7 ductal carcinoma in situ 31.8 VEGFA TP53 PGR KRT5 ESR2 ESR1
8 gynecomastia 31.7 PGR ESR2 ESR1 ERBB2
9 intraductal papilloma 31.4 PGR KRT5 ESR1 ERBB2
10 lobular neoplasia 31.4 TP53 PRLR PGR KRT5 ESR2 ESR1
11 breast ductal carcinoma 31.2 VEGFA TP53 TFF1 PGR KRT5 ESR2
12 mammary paget's disease 31.1 PGR ESR1 ERBB2
13 mammographic density 31.1 PGR IGFBP3 IGF1 ESR1 CYP1B1 CYP1A1
14 insulin-like growth factor i 31.0 IGFBP3 IGF1 ESR1 EGF
15 female breast cancer 31.0 TP53 PGR IGF1 ESR1 ERBB2 CYP1A1
16 endometriosis 31.0 VEGFA PGR MIR199A1 ESR2 ESR1 CYP1B1
17 leiomyoma 30.8 PGR ESR2 ESR1 EGF COMT
18 galactorrhea 30.8 PRLR IGF1
19 estrogen excess 30.8 PGR ESR2 ESR1
20 sporadic breast cancer 30.8 TP53 PGR ESR2 ESR1 ERBB2 BRCA1
21 tubular adenocarcinoma 30.7 PGR ESR1 ERBB2
22 bilateral breast cancer 30.7 PGR ESR1 ERBB2 BRCA1
23 cystitis 30.6 VEGFA TP53 IGF1 EGF
24 pregnancy adenoma 30.6 PGR KRT5
25 breast malignant phyllodes tumor 30.6 TP53 PGR KRT5 ESR1 ERBB2
26 meningioma, familial 30.6 VEGFA TP53 PGR IGF1 ESR1 ERBB2
27 apocrine adenocarcinoma 30.6 PGR KRT5 ESR1 ERBB2
28 inflammatory breast carcinoma 30.6 RHOC PGR ESR1 ERBB2
29 cervical cancer 30.6 VEGFA TP53 IGFBP3 ESR1 ERBB2 EGF
30 vascular disease 30.6 VEGFA TP53 MIR199A1 IGF1 CASP3
31 vulvar disease 30.6 TP53 PGR ERBB2
32 li-fraumeni syndrome 30.5 TP53 ESR1 ERBB2 BRCA1
33 skin melanoma 30.5 TP53 MIR199A1 ERBB2 CASP3
34 body mass index quantitative trait locus 11 30.5 VEGFA TP53 MIR199A1 IGFBP3 IGF1 ESR1
35 fallopian tube carcinoma 30.5 VEGFA TP53 PGR ESR1 ERBB2 BRCA1
36 breast carcinoma in situ 30.5 VEGFA TP53 PGR KRT5 ESR1 ERBB2
37 prostatic hypertrophy 30.5 PGR ESR1 EGF
38 ovarian disease 30.5 VEGFA TP53 PGR MIR199A1 IGF1 ESR2
39 gastric cancer 30.4 VEGFA TP53 TFF1 PGR MIR199A1 IGF1
40 rare non-malformative breast disease 12.1
41 mastitis 11.8
42 diabetic mastopathy 11.4
43 infant gynecomastia 11.3
44 breast abscess 11.3
45 multiple fibroadenomas of the breast 11.1
46 gastric adenocarcinoma 10.9 VEGFA TP53 TFF1 IGF1 ESR1 ERBB2
47 mixed cell adenoma 10.9 IGF1 EGF CTSD
48 endometrial clear cell adenocarcinoma 10.9 TP53 ESR1 CTSD
49 cervical adenocarcinoma 10.9 TP53 ESR1 ERBB2 EGF CASP3
50 ewing sarcoma 10.9 VEGFA TP53 IGFBP3 IGF1 ERBB2 CASP3

Graphical network of the top 20 diseases related to Breast Disease:



Diseases related to Breast Disease
Sources

Symptoms & Phenotypes for Breast Disease

About this section

UMLS symptoms related to Breast Disease:


pruritus, exanthema, pelvic pain, mastodynia, breast engorgement, nipple discharge, signs and symptoms in breast, other signs and symptoms in breast, breast pain female

GenomeRNAi Phenotypes related to Breast Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 8.92 CASP3 ERBB2 IGF1
2 Decreased viability with paclitaxel GR00179-A-2 8.92 IGF1

MGI Mouse Phenotypes related to Breast Disease:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.43 BRCA1 CASP3 COMT CTSD CYP1A1 EGF
2 homeostasis/metabolism MP:0005376 10.43 BRCA1 CASP3 COMT CTSD CYP1A1 CYP1B1
3 growth/size/body region MP:0005378 10.42 BRCA1 CASP3 CTSD CYP1A1 EGF ERBB2
4 behavior/neurological MP:0005386 10.4 BRCA1 CASP3 COMT CTSD ERBB2 ESR1
5 cellular MP:0005384 10.35 BRCA1 CASP3 CTSD ERBB2 ESR1 ESR2
6 integument MP:0010771 10.34 BRCA1 CASP3 CTSD EGF ERBB2 ESR1
7 cardiovascular system MP:0005385 10.32 BRCA1 CASP3 COMT CYP1A1 ERBB2 ESR1
8 immune system MP:0005387 10.32 BRCA1 CASP3 COMT CTSD CYP1A1 EGF
9 digestive/alimentary MP:0005381 10.31 BRCA1 CASP3 CTSD EGF ERBB2 ESR1
10 hematopoietic system MP:0005397 10.31 BRCA1 CASP3 COMT CTSD CYP1A1 ESR1
11 limbs/digits/tail MP:0005371 10.22 BRCA1 ERBB2 ESR1 ESR2 IGF1 IGFBP3
12 neoplasm MP:0002006 10.21 BRCA1 CYP1B1 ERBB2 ESR1 ESR2 IGF1
13 muscle MP:0005369 10.16 BRCA1 CASP3 ERBB2 ESR1 ESR2 IGF1
14 adipose tissue MP:0005375 10.14 BRCA1 ESR1 ESR2 IGF1 IGFBP3 PRLR
15 nervous system MP:0003631 10.14 BRCA1 CASP3 COMT CTSD ERBB2 ESR1
16 normal MP:0002873 10.02 BRCA1 CYP1A1 EGF ERBB2 ESR1 ESR2
17 no phenotypic analysis MP:0003012 9.97 CASP3 CYP1A1 ESR1 ESR2 KRT5 PGR
18 reproductive system MP:0005389 9.93 BRCA1 CASP3 COMT EGF ERBB2 ESR1
19 renal/urinary system MP:0005367 9.86 BRCA1 CASP3 COMT ESR1 ESR2 IGF1
20 respiratory system MP:0005388 9.61 BRCA1 CASP3 COMT ERBB2 ESR1 ESR2
21 skeleton MP:0005390 9.36 BRCA1 CASP3 ERBB2 ESR1 ESR2 IGF1
Sources

Drugs & Therapeutics for Breast Disease

About this section

Drugs for Breast Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 200)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
2
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
3
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
4
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
5 retinol Phase 4
6 Retinol palmitate Phase 4
7 Analgesics Phase 4
8 Hypolipidemic Agents Phase 4
9 Anti-Inflammatory Agents, Non-Steroidal Phase 4
10 Analgesics, Non-Narcotic Phase 4
11 Lipid Regulating Agents Phase 4
12 Evening Primrose Phase 4
13 Anesthetics, General Phase 4
14 Central Nervous System Depressants Phase 4
15 Anesthetics, Local Phase 4
16 Anti-Inflammatory Agents Phase 4
17 Dermatologic Agents Phase 4
18 glucocorticoids Phase 4
19 Hydrocortisone hemisuccinate Phase 4
20 Respiratory System Agents Phase 4
21 Hydrocortisone-17-butyrate Phase 4
22 Anti-Asthmatic Agents Phase 4
23 Hydrocortisone 17-butyrate 21-propionate Phase 4
24 Betamethasone benzoate Phase 4
25 Betamethasone Valerate Phase 4 2152-44-5
26 Betamethasone sodium phosphate Phase 4
27 Betamethasone-17,21-dipropionate Phase 4
28 Chelating Agents Phase 4
29 Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate Phase 4
30
Evening primrose oil Investigational, Nutraceutical Phase 4 308064-97-3
31
Remifentanil Approved Phase 3 132875-61-7 60815
32
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
33
tannic acid Approved Phase 3 1401-55-4
34
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
35
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
36
Mesna Approved, Investigational Phase 3 3375-50-6 598
37
Acetaminophen Approved Phase 3 103-90-2 1983
38
Ibuprofen Approved Phase 3 15687-27-1 3672
39
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
40
Codeine Approved, Illicit Phase 3 76-57-3 5284371
41
Acetylcholine Approved, Investigational Phase 3 51-84-3 187
42
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
43
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
44
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
45
Fulvestrant Approved, Investigational Phase 3 129453-61-8 104741 17756771
46
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
47
Lenograstim Approved, Investigational Phase 3 135968-09-1
48
Bevacizumab Approved, Investigational Phase 3 216974-75-3
49
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
50
Docetaxel Approved, Investigational Phase 2, Phase 3 114977-28-5 148124

Interventional clinical trials:

(show top 50) (show all 154)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Randomized, Open, Parallel Controlled Clinical Study on the Efficacy and Safety of the Treatment of Cyclomastopathy With Xiaoru Sanjie Capsule Unknown status NCT02929420 Phase 4 Xiaoru Sanjie capsules;Xiao Yao pills
2 The Use of Botulinum Toxin-A in Two-stage Tissue Expander/Implant Breast Reconstruction: A Prospective, Randomized, Double-Blind Placebo Controlled Trial Unknown status NCT01427400 Phase 4 Botulinum Toxin-A;Saline
3 A Single Blinded Randomized Controlled Trial of the Comparative Effects of Tamoxifen and Evening Primrose Oil in Premenopausal Non-high Risk Patients With Benign Breast Disease With Respect to the Estrogen Receptor Status. Completed NCT00999921 Phase 4 Tamoxifen;Evening Primrose Oil
4 A Phase IV Multicentre, Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination With Exemestane, With Exploratory Epigenetic Marker Analysis Completed NCT01743560 Phase 4 RAD001;Exemestane
5 Single-shot Pectoral Plane (PECs) Blocks Versus Continuous Local Anaesthetic Infusion Analgesia or Both PECs Block and Local Anaesthetic Infusion After Non-ambulatory Breast Cancer Surgery: A Prospective, Randomised, Double-blind Trial Completed NCT03024697 Phase 4
6 A Randomized Controlled Study on the Effectiveness of Local Injection Combined With Topical Steroids vs. Topical Steroids Mono-therapy in the Treatment of Idiopathic Granulomatous Mastitis Recruiting NCT03766997 Phase 4 Compound Betamethasone Injection;Hydrocortisone Butyrate 0.1% Cream
7 Evaluation of Topical Steroids and Surgical Treatment for Idiopathic Granulomatous Mastitis Recruiting NCT02959580 Phase 4 Hydrocortisone Butyrate
8 Contrast Enhanced Breast MRI: Comparison of Two Macrocyclic Gadolinium-Based Contrast Agents: Gadoterate Meglumine (Dotarem) and Gadobutrol (Gadavist). A Prospective Study. Not yet recruiting NCT03730051 Phase 4 Gadoterate meglumine;Gadobutrol
9 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of IoGenâ„¢ for the Treatment of Moderate or Severe, Periodic Breast Pain Associated With Symptomatic Fibrocystic Breast Disease Unknown status NCT00237523 Phase 3 IoGen (molecular iodine)
10 A Randomized Phase III Study of Metronomic vs. Intermittent Capecitabine Maintenance Therapy Following First-line Capecitabine and Docetaxel Therapy in HER2-negative Metastatic Breast Cancer Unknown status NCT01917279 Phase 3 Docetaxel plus Capecitabine;Capecitabine;Capecitabine
11 Randomized Controlled Trials of Diet and Lifestyle Intervention to Promote Chinese Postpartum Women's Health Unknown status NCT01039051 Phase 2, Phase 3
12 Randomized Pivotal Trial to Assess the Safety and Efficacy of Preoperative Focused Microwave Thermotherapy Plus Preoperative Chemotherapy Versus Preoperative Chemotherapy Alone for Cytoreduction of Large Breast Cancer in Female Patients With Intact Breast Unknown status NCT01204801 Phase 3 Chemotherapy (control)
13 Efficacy and Safety of Nutritional Supplement ONCOXIN in Patients With Breast Fibrocystic Disease Completed NCT00967681 Phase 3
14 Monitored Anesthesia Care Using Remifentanil and Ketofol Results in a Superior Quality of Recovery Compared With Total Intravenous Anesthesia in Ambulatory Breast Augmentation Completed NCT03764267 Phase 3 Remifentanil;general anesthetic
15 BNP7787 vs. Placebo for Prevention of Paclitaxel Neurotoxicity: A Double-Blind Multicenter Randomized Phase 3 Trial in Patients With Metastatic Breast Cancer Completed NCT00039780 Phase 3 BNP7787;Placebo
16 A Randomized Controlled Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3® for the Treatment of Pain After Breast Surgery. Completed NCT00299039 Phase 3 acetaminophen plus codeine;acetaminophen plus ibuprofen
17 TARGIT: A Randomised Controlled Trial to Compare Targeted Intra-operative Radiotherapy With Conventional Post-operative Radiotherapy After Conservative Breast Surgery for Women With Early Stage Breast Cancer Completed NCT00983684 Phase 3
18 Botulinum Toxin A in Tissue Expander Breast Reconstruction: A Double-Blinded Randomized Controlled Trial Completed NCT01591746 Phase 3 Botulinum Toxin Type A;Placebo
19 A Phase III Multicentre Double Blind Randomised Trial of Celecoxib Versus Placebo in Primary Breast Cancer Patients Completed NCT02429427 Phase 3 Celecoxib
20 A Phase III, Double-blind, Placebo-controlled, Randomized Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer. Recruiting NCT04177108 Phase 3 Atezolizumab;Ipatasertib;Paclitaxel;Placebo for Atezolizumab;Placebo for Ipatasertib
21 A Randomized Double-blind, Placebo-controlled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line of Prior Endocrine Treatment Active, not recruiting NCT02422615 Phase 3 Ribociclib;fulvestrant;Ribociclib placebo
22 A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Active, not recruiting NCT00887536 Phase 3 bevacizumab;docetaxel;doxorubicin;cyclophosphamide;pegfilgrastim
23 Prospective Randomized Controlled Study on the Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer Not yet recruiting NCT03373708 Phase 2, Phase 3 Epirubicin;Cyclophosphamide;Docetaxel;Goserelin acetate;Tamoxifen;Letrozole
24 A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease Unknown status NCT01849250 Phase 2 Docosahexaenoic Acid
25 A Randomized Pivotal Clinical Trial In Breast Cancer Patients Of Pre-Operative Focal Microwave Thermotherapy Treatment For Early-Stage Breast Disease In Intact Breast Unknown status NCT00036998 Phase 2
26 A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Multicenter Evaluation of the Use of Topically Administered Danazol Versus Placebo in Subjects With Pain Associated With Fibrocystic Breast Disease Completed NCT00744276 Phase 2 danazol;Placebo
27 A Multicenter, Open-label, Parallel, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LuminoMark Inj. (Conc. for Fluorescence) Localization in Patients With Nonpalpable Breast Lesions Completed NCT03743259 Phase 2 LuminoMark inj. 0.1mL;LuminoMark inj. 0.2mL;Charcotrace Inj.
28 An Open-Label, MultiCenter Evaluation of the Use of Topically Administered FP1198 in Subjects With Pain Associated With Cyclic Mastalgia Completed NCT01105793 Phase 2 Danazol
29 Phase II Clinical Trial of Neoadjuvant Treatment With Zolendronic Acid Plus Anthracycline and Taxane in Locally Advanced Breast Cancer Completed NCT01472146 Phase 2 Zo-Nantax
30 A Phase 2 Study of ET-743 in Subjects With Advanced Breast Cancer Completed NCT00050427 Phase 2 ET743;ET743
31 Phase II Study of Soy Protein to Treat Vasomotor Symptoms in Postmenopausal Women Taking Tamoxifen Completed NCT00031720 Phase 2 Tamoxifen
32 A Randomized, Placebo-Controlled, Parallel Treatment Group, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral DMI-5207 in Adult Subjects With Diabetic Macular Edema Completed NCT02002403 Phase 2 Danazol
33 Guaraná ("Paullinia Cupana") for Chemotherapy Related Fatigue in Breast Cancer Patients: Results Of A Pilot Double Blind Randomized Study Completed NCT01043913 Phase 2 Guarana extract
34 TARGIT-E(Elderly) Prospective Phase II Study of Intraoperative Radiotherapy (IORT) in Elderly Patients With Small Breast Cancer Completed NCT01299987 Phase 2
35 A Randomized, Double-Blind Trial, Comparing the Safety in Mothers and Their Infants and Immunogenicity in Mothers of Live Attenuated Influenza Vaccine (LAIV) to Inactivated Trivalent Influenza Vaccine (TIV) When Administered to Breast Feeding Women Completed NCT01181323 Phase 2
36 Analgesic Efficacy of Pulsed Radiofrequency in Non-cyclic Mastalgia Completed NCT03715413 Phase 2 Tamoxifen
37 A Randomized Phase II Prevention Trial in Subjects at High Risk for Hormone Non-responsive Breast Cancer Completed NCT01500577 Phase 2 nimesulide;Simvastatin
38 TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions Recruiting NCT02928978 Phase 2 Ruxolitinib;Placebo (for Ruxolitinib)
39 Circadian Thermal Sensing for the Detection of Breast Disease as a Supplemental Cancer Screening System Recruiting NCT02511301 Phase 1, Phase 2
40 A Phase I/II Trial of Leflunomide in Women With Previously Treated Metastatic Triple Negative Cancers Recruiting NCT03709446 Phase 1, Phase 2 Leflunomide
41 A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HeR-positive, Her2-positive Metastatic Breast Cancer Recruiting NCT03304080 Phase 1, Phase 2 Anastrozole;Palbociclib;Trastuzumab;Pertuzumab
42 A Randomized, Multicenter, Phase II Study of the Efficacy and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Recruiting NCT03500380 Phase 2 RC48-ADC;Lapatinib;Capecitabine
43 Vaginal Progesterone Versus Placebo for the Treatment of Vaginal Atrophy - a Double Blind Randomized Control Trial Recruiting NCT02460302 Phase 2 Vaginal progesterone;Placebo
44 Pyrotinib Maleate Combined With Trastuzumab Plus Aromatase Inhibitor in the First-line Treatment of Advanced HER2-positive/HR-positive Breast Cancer Phase II Study Not yet recruiting NCT04088110 Phase 2 Pyrotinib;Trastuzumab;Aromatase Inhibitors
45 A Randomized, Open-label Study of First Line Pyrotinib, Trastuzumab With an Aromatase Inhibitors, in the Treatment of HER2 Positive and HR Positive Metastatic or Inoperable Locally Advanced Breast Cancer Not yet recruiting NCT03910712 Phase 2 Pyrotinib;Trastuzumab;Aromatase inhibitor
46 Window Trial of Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer (a BEAUTY Study*) Not yet recruiting NCT03979508 Phase 2 Abemaciclib
47 Identifying the miR Fingerprint in NAF, Serum, and Tissue in Patients With Ductal Carcinoma in Situ (DCIS) or Invasive Breast Cancer Suspended NCT02127073 Phase 2 Intranasal Oxytocin
48 GCC 0901- A Phase II Study of Letrozole in Combination With Lapatinib Followed by an Addition of Everolimus in Postmenopausal Women With Advanced Endocrine Resistant Breast Cancer Terminated NCT01499160 Phase 2 letrozole;lapatinib;everolimus
49 A Randomized Phase 2, Open-Label Study Of CP-751,871 In Combination With Docetaxel And Docetaxel Alone As A First Line Treatment Of Patients With Advanced Breast Cancer Withdrawn NCT00678626 Phase 2 CP-751,871;Docetaxel
50 A Phase 1 Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors Completed NCT02897778 Phase 1 Entinostat

Search NIH Clinical Center for Breast Disease

Cochrane evidence based reviews: breast diseases

Sources

Genetic Tests for Breast Disease

About this section
Sources

Anatomical Context for Breast Disease

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Breast Disease:

19
Breast

MalaCards organs/tissues related to Breast Disease:

40
Breast, Thyroid, Lymph Node, Skin, Prostate, Testes, Bone
Sources

Publications for Breast Disease

About this section

Articles related to Breast Disease:

(show top 50) (show all 4693)
# Title Authors PMID Year
1
Radiological and clinical findings in sclerosing adenosis of the breast. 42
31574804 2019
2
Contrast ultrasound versus ultrasound elastography for diagnosis of breast lumps: A cross-sectional study. 42
31261536 2019
3
Surgical Management of Gynecomastia: A Review of the Current Insurance Coverage Criteria. 42
31033818 2019
4
Expression of estrogenicity genes in a lineage cell culture model of human breast cancer progression. 54 61
19308726 2010
5
Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease. 54 61
19551864 2010
6
Cells with minimal expression of the JAK/STAT pathway related proteins STAT5a and the prolactin receptor: evidence of an alternate prolactin receptor isoform in breast disease. 54 61
20214633 2010
7
Nipple aspirate fluid collection, related factors and relationship between carcinoembryonic antigen in nipple aspirate fluid and breast diseases in women in Harbin, PRC. 54 61
19273481 2009
8
Estrogen alpha and progesterone receptor expression in the normal mammary epithelium in relation to breast cancer risk. 54 61
18798271 2009
9
Caffeine consumption and the risk of breast cancer in a large prospective cohort of women. 54 61
18852405 2008
10
[mRNA expression of CK19 and CEA in peripheral blood of patients with breast cancer detected by real-time quantitative PCR]. 54 61
19087676 2008
11
The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. 54 61
17851763 2008
12
Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy. 54 61
18379196 2008
13
A comparison of plasma versus histologic indices of angiogenic markers in breast cancer. 54 61
18091379 2007
14
Importance of novel sequence alterations in the FHIT gene on formation of breast cancer. 54 61
18338496 2007
15
[Analysis of the mutation of BRCA1 gene in 70 Uigur women breast cancer patients in Xinjiang]. 54 61
17557253 2007
16
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. 54 61
17417639 2007
17
Clinical utility of serum human epidermal receptor-2/neu detection in breast cancer patients. 54 61
17431282 2007
18
IGFBP3 mRNA expression in benign and malignant breast tumors. 54 61
17210081 2007
19
The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions. 54 61
17164758 2007
20
[Role of immunocytochemistry in fine needle aspiration cytology diagnosis of mammary lesions of breast]. 54 61
17374259 2006
21
Polymorphisms in estrogen-metabolizing and estrogen receptor genes and the risk of developing breast cancer among a cohort of women with benign breast disease. 54 61
16808847 2006
22
Hormones and progeny of breast tumor cells. 54 61
16698656 2006
23
Prognostic significance of estrogen receptor Beta in epithelial hyperplasia of usual type with known outcome. 54 61
16327431 2005
24
[Expression and clinical significance of cytokeratin 19 in bone marrow of patients with breast cancer]. 54 61
15946491 2005
25
Detection of tumor markers including carcinoembryonic antigen, APC, and cyclin D2 in fine-needle aspiration fluid of breast. 54 61
15508191 2004
26
Insulin-like growth factor (IGF)-I and IGF-II serum concentrations in patients with benign and malignant breast lesions: free IGF-II is correlated with breast cancer size. 54 61
15217931 2004
27
p65 and c-erbB2 genes expression in breast tumors: comparison with some histological typing, grading and clinical staging. 54 61
12866575 2003
28
Clustering of variations and haplotype analysis in the highly variable region of exon 11 of BRCA1 in Chinese women with sporadic breast cancer. 54 61
12402341 2002
29
Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. 54 61
11839578 2002
30
Behaviour of estrogen receptor, histological correlation, and clinical outcome in patients with benign breast disorders. 54 61
12699101 2002
31
Breast cancer risk factors and HER2 over-expression in tumors. 54 61
12132871 2001
32
Association between estradiol, estrogen receptors, total lipids, triglycerides, and cholesterol in patients with benign and malignant breast tumors. 54 61
11282289 2000
33
Serum c-erbB-2 protein in breast cancer patients. 54 61
10998842 2000
34
Dissociated overexpression of cathepsin D and estrogen receptor alpha in preinvasive mammary tumors. 54 61
10836299 2000
35
Breast cancer, heterocyclic aromatic amines from meat and N-acetyltransferase 2 genotype. 54 61
10753193 2000
36
Tissue iodine content and serum-mediated 125I uptake-blocking activity in breast cancer. 54 61
10720070 2000
37
Analysis of cathepsin D in human breast cancer: usefulness of the processed 31 kDa active form of the enzyme as a prognostic indicator in node-negative and node-positive patients. 54 61
10845280 2000
38
RT-PCR amplification of CK19 mRNA in the blood of breast cancer patients: correlation with established prognostic parameters. 54 61
10845277 2000
39
HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. 54 61
10637239 2000
40
Angiogenic growth factors in preinvasive breast disease. 54 61
10537355 1999
41
The normal breast epithelium of women with breast cancer displays an aberrant response to estradiol. 54 61
10548314 1999
42
HER-2/neu (c-erb-B2) gene and protein in breast cancer. 54 61
10396301 1999
43
Serum levels of insulin-like growth factor binding protein-3 in benign and malignant breast disease. 54 61
10442920 1999
44
Receiver-operating characteristic (ROC) curve analysis of cathepsin D and pS2 in breast disease; results from a prospective study. 54 61
10629636 1999
45
Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas. 54 61
10363992 1999
46
Environmental exposure to hexachlorobenzene (HCB) and risk of female breast cancer in Connecticut. 54 61
10350435 1999
47
[Relationship of estrogen and progesterone receptors to the menstrual cycle and menopausal status at the time of breast surgery]. 54 61
10486879 1999
48
Transcriptional activation of functional endogenous estrogen receptor gene expression in MCF10AT cells: a model for early breast cancer. 54 61
9772278 1998
49
Plasma coenzyme Q10 concentrations in breast cancer: prognosis and therapeutic consequences. 54 61
9760013 1998
50
c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. 54 61
9879773 1998
Sources

Variations for Breast Disease

About this section
Sources

Expression for Breast Disease

About this section
Search GEO for disease gene expression data for Breast Disease.
Sources

Pathways for Breast Disease

About this section

Pathways related to Breast Disease according to GeneCards Suite gene sharing:

(show all 43)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.8 VEGFA TP53 RHOC IGF1 ESR2 ESR1
2
GPCR Pathway 63
Show member pathways
 13.69 VEGFA TP53 RHOC IGF1 ESR2 ESR1
3
Nanog in Mammalian ESC Pluripotency 63
Show member pathways
 13.27 VEGFA IGF1 ESR2 ESR1 ERBB2 EGF
4
PI3K-Akt signaling pathway 36
Show member pathways
 12.89 VEGFA TP53 PRLR IGF1 ERBB2 EGF
5
Endometrial cancer 36
Show member pathways
 12.85 VEGFA TP53 IGF1 ERBB2 EGF CASP3
6
MAPK signaling pathway 36 1
12.74 VEGFA TP53 IGF1 ERBB2 EGF CASP3
7
Chks in Checkpoint Regulation 63
Show member pathways
 12.66 TP53 IGF1 ESR2 ESR1 CASP3 BRCA1
8
ErbB signaling pathway 1 36
Show member pathways
 12.61 VEGFA TP53 IGF1 ERBB2 EGF
9
Pathways in cancer 36
12.58 VEGFA TP53 IGF1 ESR2 ESR1 ERBB2
10
Glioma 36
Show member pathways
 12.54 TP53 IGF1 ESR2 ESR1 ERBB2 EGF
11
Development ERBB-family signaling 22
Show member pathways
 12.48 TP53 RHOC ERBB2 EGF CASP3
12
Prolactin Signaling Pathway 1 36
Show member pathways
 12.42 PRLR ESR2 ESR1 ERBB2 CTSD CASP3
13
RhoGDI Pathway 63
Show member pathways
 12.37 VEGFA RHOC EGF CASP3
14
DNA Damage Response 1
Show member pathways
 12.33 TP53 IGFBP3 IGF1 CASP3 BRCA1
15
Gastric cancer 36
Show member pathways
 12.22 TP53 PGR IGF1 ESR2 ESR1 ERBB2
16
MicroRNAs in cancer 36
12.19 VEGFA TP53 MIR199A1 ERBB2 CYP1B1 CASP3
17
Colorectal Cancer Metastasis 63
12.18 VEGFA TP53 EGF CASP3
18
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.17 TFF1 IGF1 ESR2 ESR1 ERBB2 EGF
19
Integrated Breast Cancer Pathway 1
12.11 VEGFA TP53 ESR1 CASP3 BRCA1
20
Proteoglycans in cancer 36
12.11 VEGFA TP53 IGF1 ESR1 ERBB2 CASP3
21
Glioblastoma Multiforme 63
11.95 TP53 RHOC IGF1 EGF
22
HIF-1 signaling pathway 36
11.94 VEGFA IGF1 ERBB2 EGF
23
Signaling by ERBB4 65
Show member pathways
 11.86 PRLR PGR ESR1 ERBB2 EGF
24
Relaxin signaling pathway 36
Show member pathways
 11.82 VEGFA TFF1 PGR IGFBP3 IGF1 ESR2
25
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.76 VEGFA IGF1 EGF
26
Platinum drug resistance 36
11.72 TP53 ERBB2 CASP3 BRCA1
27
Transcription Ligand-dependent activation of the ESR1/SP pathway 22
Show member pathways
 11.71 VEGFA PRLR ESR1
28
Bladder cancer 36 1
11.71 VEGFA TP53 ERBB2 EGF
29
Steroid hormone biosynthesis 36
Show member pathways
 11.68 CYP1B1 CYP1A1 COMT
30
Pathways Affected in Adenoid Cystic Carcinoma 1
11.67 TP53 ERBB2 BRCA1
31
Celecoxib Pathway, Pharmacodynamics 60
11.61 VEGFA IGFBP3 CASP3
32
Ovarian steroidogenesis 36
11.53 IGF1 CYP1B1 CYP1A1
33
Differentiation Pathway 1
11.52 VEGFA IGF1 EGF
34
Hepatitis C and Hepatocellular Carcinoma 1
11.52 VEGFA TP53 CASP3 BRCA1
35
Integrated Cancer Pathway 1
11.49 TP53 CASP3 BRCA1
36
FOXA1 transcription factor network 1
Show member pathways
 11.49 TFF1 ESR1 BRCA1
37
Aryl Hydrocarbon Receptor 1
11.46 VEGFA ESR1 CYP1B1 CYP1A1
38
LKB1 signaling events 1
11.44 TP53 ESR1 CTSD
39
Photodynamic therapy-induced HIF-1 survival signaling 1
11.37 VEGFA TP53 IGFBP3
40
Estrogen metabolism 1
Show member pathways
 11.32 CYP1B1 CYP1A1 COMT
41
Ovarian Infertility Genes 1
11.29 PRLR PGR ESR2
42
Estrogen Receptor Pathway 1
10.83 ESR1 CYP1B1 CYP1A1
43
Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics 60
10.24 ESR2 ESR1
Sources

GO Terms for Breast Disease

About this section

Cellular components related to Breast Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet alpha granule lumen GO:0031093 9.33 VEGFA IGF1 EGF
2 insulin-like growth factor ternary complex GO:0042567 8.96 IGFBP3 IGF1
3 insulin-like growth factor binding protein complex GO:0016942 8.62 IGFBP3 IGF1

Biological processes related to Breast Disease according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.93 TP53 IGF1 ESR2 ESR1 EGF BRCA1
2 positive regulation of cell migration GO:0030335 9.91 VEGFA RHOC IGF1 EGF
3 positive regulation of apoptotic process GO:0043065 9.88 TP53 IGFBP3 CYP1B1 CTSD CASP3
4 positive regulation of protein kinase B signaling GO:0051897 9.8 MIR199A1 ESR1 ERBB2 EGF
5 negative regulation of gene expression GO:0010629 9.77 VEGFA TP53 PGR IGF1 ESR1
6 cellular response to organic cyclic compound GO:0071407 9.74 CYP1B1 CYP1A1 CASP3
7 positive regulation of epithelial cell proliferation GO:0050679 9.73 VEGFA IGF1 ERBB2
8 positive regulation of angiogenesis GO:0045766 9.73 VEGFA MIR199A1 CYP1B1 BRCA1
9 positive regulation of gene expression GO:0010628 9.73 VEGFA TP53 IGF1 ERBB2 EGF BRCA1
10 response to estrogen GO:0043627 9.72 ESR1 COMT BRCA1
11 positive regulation of MAP kinase activity GO:0043406 9.71 VEGFA ERBB2 EGF
12 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.6 TP53 ESR1
13 omega-hydroxylase P450 pathway GO:0097267 9.59 CYP1B1 CYP1A1
14 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.58 TP53 ESR1
15 toxin metabolic process GO:0009404 9.58 CYP1B1 CYP1A1
16 negative regulation of smooth muscle cell proliferation GO:0048662 9.58 TP53 IGFBP3 COMT
17 negative regulation of ERBB signaling pathway GO:1901185 9.52 ERBB2 EGF
18 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.51 VEGFA TP53
19 response to antibiotic GO:0046677 9.5 TP53 CYP1A1 CASP3
20 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.46 VEGFA TP53 IGF1 EGF
21 estrogen metabolic process GO:0008210 9.13 CYP1B1 CYP1A1 COMT
22 mammary gland alveolus development GO:0060749 8.8 VEGFA ESR1 EGF

Molecular functions related to Breast Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.36 VEGFA TP53 TFF1 RHOC PRLR PGR
2 identical protein binding GO:0042802 10 VEGFA TP53 PGR ESR2 ESR1 ERBB2
3 growth factor activity GO:0008083 9.67 VEGFA TFF1 IGF1 EGF
4 steroid hormone receptor activity GO:0003707 9.61 PGR ESR2 ESR1
5 estrogen 16-alpha-hydroxylase activity GO:0101020 9.48 CYP1B1 CYP1A1
6 nuclear receptor activity GO:0004879 9.43 PGR ESR2 ESR1
7 estrogen receptor activity GO:0030284 9.32 ESR2 ESR1
8 estrogen response element binding GO:0034056 9.16 ESR2 ESR1
9 steroid binding GO:0005496 9.13 PGR ESR2 ESR1
10 enzyme binding GO:0019899 9.1 TP53 PGR ESR2 ESR1 CYP1A1 BRCA1
Sources

Sources for Breast Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....